Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic Colorectal Cancer
Last updated August 21, 2017
Status:
Negotiations were not pursued
Manufacturer:
Takeda Canada Inc.
Indication:
Multiple Myeloma
Last updated August 18, 2017
Status:
Concluded without agreement
Manufacturer:
Purdue Pharma
Indication:
Pain, persistent (moderate intensity)
Last updated August 18, 2017
Status:
Concluded without agreement
Manufacturer:
Sanofi Genzyme Canada
Indication:
Medullary Thyroid Cancer
Last updated August 16, 2017
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Polycythemia vera
Last updated August 8, 2017
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Non-Small Cell Lung Cancer (with CNS metastases)
Last updated July 31, 2017
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated July 7, 2017
Mifegymiso (mifepristone and misoprostol)
Status:
Concluded with an LOI
Manufacturer:
Celopharma
Indication:
Medical termination of pregnancy
Last updated July 5, 2017
Votrient (pazopanib hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Metastatic Renal Cell Carcinoma
Last updated July 3, 2017
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Last updated June 27, 2017